Crossmark

Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s00280-018-3598-4

Published Online: 2018-05-04

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koba, Taro

Minami, Seigo

Nishijima-Futami, Yu

Masuhiro, Kentaro

Kimura, Hiromi

Futami, Shinji

Yaga, Moto

Mori, Masahide

Kagawa, Hiroyuki

Uenami, Takeshi

Kohmo, Satoshi

Otsuka, Tomoyuki

Yamamoto, Suguru

Komuta, Kiyoshi

Kijima, Takashi
License Information

Text and Data Mining valid from 2018-05-04
More Information

Article History

Received: 19 December 2017

Accepted: 1 May 2018

First Online: 4 May 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below